---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-224214"
form_type: "8-K"
ticker: "FBRX"
cik: "0001419041"
company_name: "Forte Biosciences, Inc."
filed_at: "2026-05-14T20:42:13+00:00"
generated_at: "2026-05-14T20:44:00.199104+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Forte Q1 net loss $22.1M; FB102 gets FDA Fast Track; raised $172.5M in April

## Summary
- Q1 2026 net loss $22.1M ($1.24 per share); cash $58.2M at March 31, 2026.
- FB102 received FDA Fast Track Designation for celiac disease; phase 2 topline results expected in 2026.
- Phase 1b vitiligo data expected shortly; alopecia areata data readout in 2026.
- R&D expenses rose to $20.5M from $12.7M YoY due to increased clinical and preclinical costs.
- In April 2026, raised $172.5M gross via equity offering, issuing 6.6M common shares.

## SEC filing metadata
- accession: 0001193125-26-224214
- form_type: 8-K
- ticker: FBRX
- cik: 0001419041
- company_name: Forte Biosciences, Inc.
- filed_at: 2026-05-14T20:42:13+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419041/000119312526224214/0001193125-26-224214-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419041/000119312526224214/d95486d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-224214
- JSON: https://secwatch.observer/filing/0001193125-26-224214.json
- Plain text: https://secwatch.observer/filing/0001193125-26-224214.txt

## Key facts
- Earnings Releases
  Forte Biosciences, Inc. reported the quarter ended March 31, 2026 results: net income Net loss per share - basic and diluted $ (1.24 ), EPS $(1.24).
  - Period: the quarter ended March 31, 2026
  - Net income: Net loss per share - basic and diluted $ (1.24 )
  - EPS: $(1.24)
  - Result: reported results
  source text: Forte Biosciences, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1419041/000119312526224214/0001193125-26-224214-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.